MEDICLINIC GROUP LIMITED

ANNUAL REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2026

CONTENTS

ANNUAL REPORT AND FINANCIAL STATEMENTS

MEDICLINIC GROUP LIMITED

COMPANY INFORMATION

DIRECTORS	Ela Aponte-Soyuer Alexa Aponte-Vago Jan Jonathan Durand** Alexander Victor Elias** Hughes Favard* Bertrand Levrat Petrus Jurgens Myburgh Dr Carel Aron van der Merwe Carel Petrus Francois Vosloo**

**Stefan Crouse appointed as alternate directors

COMPANY SECRETARY	MUFG Corporate Markets
COMPANY REGISTRATION NUMBER	08338604
REGISTERED OFFICE	19th Floor 51 Lime Street London EC3M 7DQ United Kingdom *Incorporated and registered in England and Wales*

MEDICLINIC GROUP LIMITED

STRATEGIC REPORT

FOR THE YEAR ENDED 31 MARCH 2026

The directors present their strategic report on Mediclinic Group Limited (the 'Company' or 'Mediclinic') for the year ended 31 March 2026

BUSINESS REVIEW AND PRINCIPAL ACTIVITIES
The Company's principal activity is to act as an intermediary holding company within the group comprising Mediclinic Holdings Limited (formerly Manta Bidco Limited) and its subsidiaries (the 'Group') Mediclinic Holdings Limited is a private company limited by shares incorporated in England and Wales The results of the Company are included in the consolidated financial statements of the Group for the year ended 31 March 2026 Mediclinic Holdings Limited is jointly owned by Remgro Limited (through certain subsidiaries) and Investment Holding Limited SARL ('IHL'), a wholly owned subsidiary of MSC Mediterranean Shipping Company Holding SA

On 26 May 2023, a Scheme of Arrangement became effective, at which point Mediclinic Holdings Limited acquired the entire share capital of Mediclinic International plc ('Mediclinic') Mediclinic was delisted from the LSE on 30 May 2023 and the JSE and NSX on 7 June 2023, and re-registered as Mediclinic Group Limited – a private company limited by shares – on 6 June 2023 Please refer to note 16 for further details regarding the immediate parent undertaking

PRINCIPAL RISKS AND UNCERTAINTIES
The Company is a wholly owned subsidiary of its UK parent, Mediclinic Holdings Limited, and the principal risks and uncertainties facing the Company are integrated with the principal risks and uncertainties facing the Group and are not managed separately Details of the risks and uncertainties facing the Group, the Group's financial risk management policy and an analysis of the performance of the Group, including key performance indicators, can be found in the Group's Annual Report for the year ended 31 March 2026 which does not form part of this report This report is available from the Company's registered office and from the Companies House website, as set out in note 15 of the financial statements

Under Section 172 of the Companies Act 2006 (Section 172'), the directors of the Company have a duty to act in a manner that they consider, in good faith, would be most likely to promote the success of Mediclinic Holdings to the benefit of its shareholders as a whole, having regard to
(A) the likely consequences of any decision in the long term,
(B) the interests of the Company's employees
(C) the need to foster the Company's business relationships with suppliers, customers and others,
(D) the impact of the Company's operations on the community and the environment,
(E) the desirability of the Company maintaining a reputation for high standards of business conduct, and
(F) the need to act fairly between members of the Company

The Group's key stakeholders and their significance to the Group are set out below
(1) CLIENTS – its business is built on its clients' wellbeing and its ability to build long-term relationships with them
(2) EMPLOYEES, ALUMNI AND POTENTIAL APPLICANTS – its workforce is key to maintaining high standards and achieving Mediclinic's strategic and ESG goals
(3) GOVERNMENTS AND AUTHORITIES – compliance with applicable legislation and regulations safeguards its ability to offer services
(4) HEALTHCARE INSURERS – privately insured patients constitute its largest client base
(5) HEALTHCARE PROFESSIONALS – healthcare professionals enable its continued success and ability to provide holistic medical care, improving patient outcomes
(6) SHAREHOLDERS – the Company is committed to maximising long-term shareholder value in whatever form when making decisions

The Group adopted a combination of formal and informal methods to engage with its key stakeholder groups on a regular or ad hoc basis, involving members of the Board as required The ESG Committee and the Board review these at least annually and consider whether the methods of engagement are effective Where relevant, papers presented to the Board and its committees drew out directors' duties under Section 172 and the interests and feedback from stakeholders, to ensure these matters were duly considered within discussions and decisions made

MEDICLINIC GROUP LIMITED

STRATEGIC REPORT (continued)

FOR THE YEAR ENDED 31 MARCH 2026

SECTION 172 STATEMENT (continued)

During the year, the Board discussed and made decisions on several matters crucial to promoting the Group's purpose, strategy and success, in each case having regard to the relevant matters set out in Section 172, as illustrated by the examples in the table below

SECTION 172 FACTORS	KEY STAKEHOLDER GROUPS	BOARD DISCUSSIONS AND DECISIONS KEY CONSIDERATIONS AND OUTCOMES
Dividend		
(A) to (F)	(6)	*The Board recommended to shareholders the payment of a final dividend of $27m for the period* ended 31 March 2026 The Board was mindful of its duties under Section 172 in respect of capital distribution and considered whether the declaration of a dividend would support the long term sustainable success of the Company and align with shareholder expectations The financial implications of capital distribution, including the ability of the Company to continue supporting its clients and maintaining financial stability, were considered by the Board
Review of Group operating model		
(A) to (F)	(1) to (6)	Following a strategic review of the Company, the Board implemented a new operating model to shape the Company's next chapter The changes simplify and streamline the organisation to drive greater accountability and safe, sustainable, profitable growth through focusing on the most compelling opportunities to deliver long-term shareholder value
Availability of healthcare professionals		
(A), (B), (C) and (E)	(1), (2), (3), (5) and (6)	In common with other healthcare providers, the Group faces challenges in terms of recruiting and retaining skilled healthcare professionals, particularly qualified and experienced nursing and other healthcare employees Mediclinic's management is implementing several initiatives to attract and retain doctors and nurses The Clinical Performance Committee closely monitors progress on the implementation of these strategies and their impact KPIs tracking progress in this area are reported on at every Board meeting
Restructuring of interests in the Company		
(A) to (F)	(1), (2), (3) and (6)	During the year, an implementation agreement signed between shareholders was announced to restructure the shareholders' interests in the Mediclinic Group The Board considered the potential impact on key stakeholders and was satisfied that appropriate measures are in place to mitigate disruption, maintain service quality and support a smooth transition with the objective of enabling a more focused regional ownership structure

NON-FINANCIAL INFORMATION AND SUSTAINABILITY REPORTING STATEMENT

The directors consider that the Group Strategic Report included in Mediclinic Holdings Limited's Annual Report for the financial year ended 31 March 2026, includes all the relevant non-financial and sustainability information relevant for the Company The Company has therefore adopted the exemption permitted under sections 414CA(7) and (8) of the Companies Act 2006 and did not publish a non-financial and sustainability information statement in its own right

REVIEW OF THE FINANCIAL PERFORMANCE AND KEY PERFORMANCE INDICATORS

The Company made a loss before taxation of $585m for the year ended 31 March 2026 (2025 loss of $415m)

At 31 March 2026 the Company had a net asset position of $3 357m (2025 $3 966m)

MEDICLINIC GROUP LIMITED

STRATEGIC REPORT (continued)

FOR THE YEAR ENDED 31 MARCH 2025

REVIEW OF THE FINANCIAL PERFORMANCE AND KEY PERFORMANCE INDICATORS (continued)

The Company is a wholly owned subsidiary of its UK parent, Mediclinic Holdings Limited, and therefore the Company's key performance indicators are integrated with the Group The directors believe that analysis using key performance indicators is not necessary for an understanding of the development, performance or position of the business of the Company and is therefore not disclosed

Since Mediclinic Group Limited is no longer the ultimate holding company of the Mediclinic Group, the Company has adopted the Financial Reporting Standard 101, 'Reduced Disclosure Framework' (FRS 101) The effect of the change had no impact on the entity's financial position and/or financial performance

The Strategic Report set out on pages 2 to 4 was approved by the Board of Directors signed on its behalf by

DocuSigned by
0D503D3D06CA46C...
Dr Carel Aron van der Merwe

Signed by
Jurgens Myburgh
Petrus Jurgens Myburgh

21 May 2026

Date

ИEDICLINIC GROUP LIMITED

⟩IRECTORS' REPORT

OR THE YEAR ENDED 31 MARCH 2026

he directors present their report and the unaudited financial statements for the year ended 31 March 2026

IRECTORS

he directors who were in office during the year and up to the date of signing the financial statements were

irector	Date appointed / resigned
la Aponte-Soyuer*	Appointed 8 June 2023
lexa Aponte-Vago*	Appointed 8 June 2023
an Jonathan Durand**	Appointed 15 February 2016
lexander Victor Elias**	Appointed 8 June 2023
lughes Favard*	Appointed 8 June 2023
ertrand Levrat	Appointed 1 June 2024
etrus Jurgens Myburgh	Appointed 1 August 2016
ɪr Carel Aron van der Merwe	Appointed 1 June 2018
arel Petrus Francois Vosloo**	Appointed 28 March 2024

Nith effect from 24 May 2024, Mr Sebastien Coquard was appointed as an alternate director for Mr Hughes Favard, Mrs Ela Aponte-ouer, and Mrs Alexa Aponte Vago Mr Sébastien Coquard resigned with effect from 18 August 2025

'Mr Stefan Crouse was appointed as an alternate director for Messrs Jan Durand and Pieter Uys, with effect from 8 June 2023, for lexander Elias with effect from 11 March 2024, and for Carel Vosloo with effect from 28 March 2024

he Company Secretary who held office during the year and up to the date of this report was
IUFG Corporate Markets

UTURE DEVELOPMENTS

he Company's future developments are integrated with the strategy of the Group and are not managed separately Details of the future rategy of the Group can be found in the Group's Annual Report for the year ended 31 March 2026 This report is available from the roup's registered office and from the Companies House website, as set out in note 16 to the financial statements

n 30 March 2026, Remgro Limited and IHL entered into an implementation agreement regarding a restructuring of their respective terests in Mediclinic Holdings

nder the terms of the restructuring
Remgro will acquire full ownership of Mediclinic International Proprietary Limited and all of its subsidiaries and associates, comprising e Group's operations in South Africa and Namibia ("MCSA Group"), for a purchase consideration of $950m, and
HL will acquire full ownership of Hirslanden AG and all of its subsidiaries and associates, comprising the Group's Swiss operations Hirslanden Group"), for a purchase consideration of $950m

e parties will retain their existing joint ownership interests in Emirates Healthcare FZ LLC and its subsidiaries and associates, mprising the Group's operations in the Middle East, and their minority interest in Spire Healthcare Group plc indirectly through ediclinic Holdings

e proposed restructuring is subject to customary regulatory and competition authority approvals but is expected to be completed within elve months of reporting date

SULTS AND DIVIDENDS

e Company made a loss for the year of $585m (2025 loss of $415m)

ιdends of $23 870 961 (2025 $23 870 961) were declared or paid during the year under review

ı 21 May 2026, the Board proposed a final dividend of $26 854 830 for the year ending 31 March 2026, which was approved by the mpany's shareholders on the same date

THORISED AND ISSUED SHARE CAPITAL

fer to note 14 of the financial statements for detail of authorised and issued share capital

MEDICLINIC GROUP LIMITED

DIRECTORS' REPORT (continued)

FOR THE YEAR ENDED 31 MARCH 2026

FINANCIAL RISK MANAGEMENT
Treasury policy and procedures are in place to identify risks associated with treasury activities and to set policies and procedures to the identified risks

Liquidity and interest rate risk
There is not considered to be a material liquidity or interest rate risk

Foreign currency risk
There is not considered to be a material foreign currency risk

STATEMENT OF DIRECTORS' RESPONSIBILITIES IN RESPECT OF FINANCIAL STATEMENTS
The directors are responsible for preparing the Annual Report and the Financial Statements in accordance with applicable law and regulation

Company law requires the directors to prepare financial statements for each financial year Under the law the directors have prepared the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 101 'Reduced Disclosure Framework', and applicable law)

Under company law, directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period In preparing the financial statements, the directors are required to

- select suitable accounting policies and then apply them consistently
- state whether applicable United Kingdom Accounting Standards, comprising FRS 101, have been followed, subject to any material departures disclosed and explained in the financial statements,
- make judgements and accounting estimates that are reasonable and prudent, and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business

The directors are responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities

The directors are also responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006

QUALIFYING THIRD PARTY INDEMNITY PROVISIONS
As permitted by the Articles of Association, each of the directors and the secretary has the benefit of an indemnity as defined by section 234 of Companies Act 2006 The indemnity remains in force throughout, and in respect of the tenure of each individual's directorship The Company has maintained the benefit of directors' and officers' liability of insurance in respect of itself and its directors' throughout the financial year and also at the date of approval of the financial statements

POST BALANCE SHEET EVENTS
On 21 May 2026, the Board proposed a final dividend of $26 9m for the year ending 31 March 2026, which was approved by the Company's shareholders on the same date

The directors are not aware of any other matter or circumstance arising since the end of the financial year that would significantly affect the operations of the Company or the results of its operations ıcusıgn Envelope ID 0A451F62-00B9-879E-8002-98B3E88817AE

/IEDICLINIC GROUP LIMITED

)IRECTORS' REPORT (continued)

OR THE YEAR ENDED 31 MARCH 2026

TREAMLINED ENERGY & CARBON REPORTING

he Company ıs a wholly owned UK subsıdıary of Medıclınıc Holdıngs Lımıted Medıclınıc Holdıngs Lımıted ıncludes ınformatıon of the ıroup's emıssıons ın ıts Annual Report for the year ended 31 March 2026 (wıthın the Strategıc Report) Thıs ıs avaılable on the ompanıes House websıte As a wholly owned subsıdıary, and because UK emıssıons are below reportıng thresholds, Streamlıned nergy and Carbon Reportıng dısclosures are not ıncluded ın thıs Annual Report

,UDIT EXEMPTION

or the year ended 31 March 2026, the Company ıs exempt from the requırement to have ıts fınancıal statements audıted under section 79A of the Companıes Act 2006, by vırtue of the guarantee provıded by Medıclınıc Holdıngs Lımıted, company regıstratıon number, a ompany ıncorporated ın, England and Wales

/lediclinic Holdings Limited has agreed to guarantee all outstandıng lıabılıtıes to whıch the company ıs subject at the end of the fınancıal ear ın accordance wıth sectıon 479C of the Companıes Act 2006

he report was approved by the Board of Dırectors and sıgned on ıts behalf by

— DocuSigned by

00503030086CA46C

)r Carel Aron van der Merwe

Signed by

Jurgens Myburgh

31460DECB2894CB

Petrus Jurgens Myburgh

'1 May 2026

)ate

MEDICLINIC GROUP LIMITED

STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED 31 MARCH 2026

	Notes	2026 $'m	2025 $'m
Administrative expenses		(6)	(4)
Other gains and losses		(3)	1
Impairment losses recognised on investments	4	(683)	(544)
Other income	5	101	128
Operating loss	6	**(591)**	**(419)**
Finance income	8	6	4
Finance costs	8	-	-
Finance income - net	8	**6**	**4**
Loss before income tax		**(585)**	**(415)**
Income tax expense	9	-	-
Loss for the financial year		**(585)**	**(415)**
Other comprehensive income / (loss)		-	-
Total comprehensive loss for the financial year		**(585)**	**(415)**

The notes on pages 11 to 32 form an integral part of these financial statements

usign Envelope ID 0A451F62-00B9-879E-8002-98B3E88817AE

MEDICLINIC GROUP LIMITED

STATEMENT OF FINANCIAL POSITION

AT 31 MARCH 2026

	Notes	2026 $'m	2025 $'m
ASSETS			
NON CURRENT ASSETS			
Investments	10	3 154	3 837
Loans to group companies	11	63	-
TOTAL NON CURRENT ASSETS		3 217	3 837
CURRENT ASSETS			
Trade and other receivables	12	-	1
Cash and cash equivalents	13	141	128
TOTAL CURRENT ASSETS		141	129
Creditors amounts falling due within one year	14	(1)	-
NET CURRENT ASSETS		140	129
TOTAL ASSETS LESS CURRENT LIABILITIES		3 357	3 966
NET ASSETS		3 357	3 966
EQUITY			
Called up share capital	15	108	108
Share premium account		1 000	1 000
Capital redemption reserve		9	9
Retained earnings		2 240	2 849
TOTAL EQUITY		3 357	3 966

These financial statements as set out on pages 8 to 32 were approved and authorised for issue by the Board of Directors and signed on its behalf by

For the year ending 31 March 2026, the company was entitled to exemption from audit under section 479a of the Companies Act 2006 (the 'Act") relating to subsidiary companies No members have required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Act The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts

DocuSigned by

0D5030306CA48C

Dr Carel Aron van der Merwe
Group Chief Executive Officer

Signed by

Jurgens Myburgh

31440DECB2694C8

Petrus Jurgens Myburgh
Group Chief Financial Officer

21 May 2026

Date

Mediclinic Group Limited (Company no 08338604)

The notes on pages 11 to 32 form an integral part of these financial statements

MEDICLINIC GROUP LIMITED

STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 MARCH 2026

	Share capital $'m	Share premium account $'m	Capital Redemption Reserve $'m	Retained earnings $'m	Total $'m
At 1 April 2024	108	1 000	9	3 288	4 405
Total comprehensive loss for the year	-	-	-	(415)	(415)
Dividends paid in the year	-	-	-	(24)	(24)
At 31 March 2025	**108**	**1 000**	**9**	**2 849**	**3 966**
Total comprehensive loss for the year	-	-	-	(585)	(585)
Dividends paid in the year	-	-	-	(24)	(24)
At 31 March 2026	**108**	**1 000**	**9**	**2 240**	**3 357**
Note	15				

The notes on pages 11 to 32 form an integral part of these financial statements

1 General information

Mediclinic Group Limited (the 'Company' or 'Mediclinic') is a private company limited by shares The Company was incorporated and registered in England and Wales under Companies Act 2006 with registered number 08338604 on 20 December 2012 Its registered address is 19th Floor, 51 Lime Street London EC3M 7DQ United Kingdom

The Company's principal activity is to act as an intermediary holding company within the group comprising Mediclinic Holdings Limited and its subsidiaries (the 'Group') The activities of its subsidiaries in Switzerland Southern Africa (South Africa and Namibia) and the Middle East (the UAE) are the operation of hospitals and clinics, and the sale of pharmaceuticals medical supplies and related equipment

These financial statements are the financial statements of the Company only Copies of the financial statements can be obtained from the Company's registered office and from the Companies House website

2 Accounting policies

The principal accounting policies applied in the preparation of these financial statements are set out below These policies have been consistently applied to all the years presented unless otherwise stated

2 1 Basis of preparation

The financial statements of Mediclinic Group Limited have been prepared in accordance with Financial Reporting Standard 101 'Reduced Disclosure Framework' (FRS 101) The financial statements have been prepared under the historical cost convention and in accordance with the Companies Act 2006

The preparation of financial statements in conformity with FRS 101 requires the use of certain critical accounting estimates It also requires management to exercise its judgement in the process of applying the company s accounting policies The areas involving a higher degree of judgement or complexity or areas where assumptions and estimates are significant to the financial statements are disclosed in note 3

The following exemptions from the requirements of IFRS have been applied in the preparation of these financial statements, in accordance with FRS 101

- IFRS 7, 'Financial Instrument Disclosures'
- IAS 7 'Statement of cash flows
- The requirements in IAS 24 to disclose related party transactions entered into between two or more members of a group
- The requirements of paragraphs 17 and 18A of IAS 24 Related Party Disclosures

2 2 Exemption from preparing consolidated financial statements

The Company is a parent company that is also a subsidiary included in the consolidated financial statements of Mediclinic Holdings Limited the Company's immediate parent established under the law of any part of the United Kingdom The Company is therefore exempt from the requirement to prepare consolidated financial statements under section 400 of the Companies Act 2006 Please refer to note 16 for further details regarding Mediclinic Holdings Limited Copies of the Mediclinic Holdings Limited consolidated financial statements can be obtained from the Company's registered office and from the Companies House website

2 3 Going concern

The Company does not have significant creditors The directors believe that it is appropriate for the financial statements to be prepared on a going concern basis The directors believe that the Company will continue to be in operation for at least 12 months from the date of this report and in the foreseeable future

MEDICLINIC GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

2 Accounting policies (continued)

2 4 New standards, amendments, IFRIC interpretations and new relevant disclosure requirements

Published standards, amendments and interpretations effective for the 31 March 2026 financial period

The following new accounting standards, interpretations and amendments adopted on 1 April 2025, had no material impact on the financial statements

- Lack of Exchangeability – Amendments to IAS 21 (1 January 2025)

The implementation of these standards and amendments had no material financial impact on the reported results or financial position of the Company

Published standards, amendments and interpretations not yet effective and not early adopted

The following new accounting standards interpretations and amendments will have no material impact on the financial statements

- *Classification and Measurement of Financial Instruments Amendments to IFRS 9 and IFRS 7 (1 January 2026)*
- Contracts Referencing Nature dependent Electricity Amendment to *IFRS 9* and *IFRS 7 (1 January 2026)*
- *IFRS 19 Subsidiaries without Public Accountability Disclosures (1 January 2027)*

The following new standard is expected to have an impact on the financial statements

IFRS 18 - Presentation and Disclosure in Financial Statements (1 January 2027)

IFRS 18 will replace IAS 1 Presentation of financial statements, introducing new requirements that will help to achieve comparability of the financial performance of similar entities and provide more relevant information and transparency to users Even though IFRS 18 will not impact the recognition or measurement of items in the financial statements, its impacts on presentation and disclosure are expected to be pervasive, in particular those related to the statement of financial performance and providing management-defined performance measures within the financial statements

Management is currently assessing the detailed implications of applying the new standard on the Group s consolidated financial statements

From the high-level preliminary assessment performed the following potential impacts have been identified

- The line items presented on the primary financial statements might change as a result of the application of the concept of useful structured summary and the enhanced principles on aggregation and disaggregation
- There will be significant new disclosures required for management-defined performance measures and for the first annual period of application of IFRS 18 a reconciliation for each line item in the statement of profit or loss between the restated amounts presented by applying IFRS 18 and the amounts previously presented applying IAS 1
- From a cash flow statement perspective, there will be changes to how interest received and interest paid are presented Interest paid will be presented as financing cash flows and interest received as investing cash flows which is a change from current presentation as part of operating cash flows

The company will apply the new standard from its mandatory effective date from the year ended 31 March 2020 Retrospective application is required and so the comparative information for the financial year ending 31 March 2027 will be restated in accordance with IFRS 18

MEDICLINIC GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS
OR THE YEAR ENDED 31 MARCH 2026

2 Accounting policies (continued)

2 5 Foreign currency translation

Functional and presentation currency

The Company's functional and presentation currency is US dollars due to the fact that the majority of operating costs and bank balances are denominated in US dollars and the Company is an intermediate holding company of Mediclinic Holdings Limited which also has a functional and presentation currency in US dollars

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions

At the end of each period foreign currency monetary items are translated using the closing rate Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges

Foreign exchange gain and losses that relate to borrowings and cash and cash equivalents are presented in the Statement of Comprehensive Income within "finance income or costs" All other foreign exchange gains and losses are presented in the income statement within "other operating income"

2 6 Rounding of amounts

All amounts in the financial statements and notes have been rounded off to the nearest million United States Dollar unless otherwise stated

3 Critical accounting estimates and judgements

Estimates and judgements are continually evaluated and are based on historical experience and other factors including expectations of future events that are believed to be reasonable under the circumstances

Critical accounting estimates and assumptions

The company makes estimates and assumptions concerning the future The resulting accounting estimates will, by definition seldom equal the related actual results The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the net financial year are addressed below

Recoverable value of investments

The carrying values of investments are reviewed for impairment only when events indicate the carrying value may be impaired Impairment indicators include both internal and external factors Example of internal factors include analysing performance against budgets and assessing absolute financial measures for indicators of impairment Examples of external considerations assessed for indications of impairment include wide economic factors such as economic growth rates

Where impairment indicators are present the recoverable amounts of assets are measured Asset recoverability requires assessment as to whether the carrying value of assets can be supported by the net present value of future cash flows derived from such assets using cash flow projections which have been discounted at an appropriate rate In calculating the net present value of the future cash flows certain assumptions are required to be made in respect of uncertain matters In particular, management has regard to assumptions in respect of revenue mix and growth rates EBITDA margins timing and amount of capital expenditure long-term growth rates and the discount rate appropriate for each CGU

MEDICLINIC GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

3 Critical accounting estimates and judgements (continued)

Critical judgements in applying the entity's accounting policies
No significant accounting judgements have been applied in the financial statements

4 Net impairment losses recognised on Investments

During the year, the following losses were recognised in profit or loss in relation to impaired investments

	2026 $'m	2025 $'m
Impairment losses (refer to note 10)	683	544
	683	**544**

5 Other income

Other income is recognised on the following basis
- Dividend income is recognised when the right to receive payment is established
- Other other income is recognised in profit or loss when it becomes receivable

	2026 $'m	2025 $'m
Dividend income	101	128
	101	**128**

6 Operating loss

	2026 $'m	2025 $'m
Operating loss is stated after charging		
Management fees	3	3
Auditors' fees[1]	1	1
Consultancy fees	2	1
Other losses/(gains)	3	(1)
Impairment losses on Investments (refer to note 10)	683	544
Other income	(101)	(128)
	591	**420**

The Company had no employees during the current or prior year

Note

1 The Company incurred an amount of $822 855 (2025 $713 787) to its auditors in respect of the audit of the Group's consolidated financial statements for the year ended 31 March 2026 No audit was performed on the Company's financial statements for the year ended 31 March 2026

7 Directors' emoluments

The directors' emoluments were as follows

	2026 $'m	2025 $'m
Aggregate emoluments	7.8	5.2

Highest paid director

The highest paid director's emoluments were as follows

	2026 $'m	2025 $'m
Total amount of emoluments	3.5	2.3

Three directors were compensated for their services either by payments received from Mediclinic Group Limited or by payments received from Mediclinic Group Services (Pty) Ltd

8 Finance income and costs

Finance income is recognised using the effective interest rate method In calculating finance income, the effective interest is applied to the gross carrying amount of the asset, when the asset is not impaired

	2026 $'m	2025 $'m
Finance income		
Bank interest income	6	4
Total finance income	6	4
Net finance cost		
Finance income	6	4
Finance costs	-	-
Net finance income	6	4

9 Income tax expense

The tax expense for the year comprises current and deferred tax Tax is recognised in the income statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity In this case, the tax is also recognised in other comprehensive income or directly in equity, respectively

The current tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the countries where the company operates and generates taxable income Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation It establishes provisions, where appropriate, on the basis of amounts expected to be paid to the tax authorities

	2026 $'m	2025 $'m
Reconciliation of taxation per income statement		
Expected tax expense at applicable tax rate	(146)	(104)
Adjusted for		
Non-taxable income	(27)	(32)
Non-deductible expenses	173	136
Income tax expense	-	-
Effective tax rate	0%	0%

The Company had unutilised tax losses of approximately $84m (2025 $83m) No deferred tax asset has been recognised in respect of these losses due to the unpredictability and availability of future taxable profit streams

10 Investments

Investments in subsidiaries are held at cost less accumulated impairment losses

	2026 $'m	2025 $'m
Shares at cost	10 024	10 024
Less accumulated impairment charge	(6 978)	(6 295)
Capital contribution	108	108
	3 154	**3 837**

The investments held by the Company are Mediclinic CHF Finco Limited, Mediclinic Luxembourg S à r l (2025 Mediclinic Holdings Netherlands B V)[1], Mediclinic Middle East Holdings Limited Mediclinic International (Pty) Limited (formerly Mediclinic International (RF) (Pty) Limited) and Mediclinic IPCo Holdings Limited being wholly owned subsidiaries The activities of the subsidiaries are the operation of hospitals and clinics and the sale of pharmaceuticals medical supplies and related equipment

Refer to note 16 regarding direct and indirect subsidiary joint venture and associate undertakings

Impairment assessment

The Company has assessed if there are any indicators of impairment of the investment in subsidiaries as at 31 March 2026

On 30 March 2026 Remgro Limited and IHL entered into an implementation agreement regarding a restructuring of their respective interests in Mediclinic Holdings

Under the terms of the restructuring
- Remgro will acquire full ownership of Mediclinic International Proprietary Limited and all of its subsidiaries and associates, comprising the Group's operations in South Africa and Namibia ("MCSA Group"), for a purchase consideration of $950m, and
- IHL will acquire full ownership of Hirslanden AG and all of its subsidiaries and associates comprising the Group's Swiss operations ("Hirslanden Group") for a purchase consideration of $950m

The parties will retain their existing joint ownership interests in Emirates Healthcare FZ LLC and its subsidiaries and associates comprising the Group's operations in the Middle East and their minority interest in Spire Healthcare Group plc indirectly through Mediclinic Holdings

The proposed restructuring is subject to customary regulatory and competition authority approvals but is expected to be completed within twelve months of reporting date

At 31 March 2026, an impairment charge of $683m was recognised in respect of the carrying value of the investment in Mediclinic Luxembourg S a r l The investment was impaired due to the consideration offered by IHL for the Swiss division (Hirslanden) in terms of the restructuring of interests in Mediclinic Holdings

In the prior year an impairment charge of $528m was recognised in respect of the carrying value of Mediclinic Holdings Netherlands B V , being the indirect shareholder of the Swiss business, due to updated estimates of future cash flows and earnings In addition, $16m was recognised in respect of the carrying amount Mediclinic IPCo Holdings Limited due to the anticipated restructuring and operating model change within the Mediclinic Group

Note

[1] *With effect from 25 March 2026 Mediclinic Holdings Netherlands B V have been deregistered All assets and liabilities of the company at this date was transferred to Mediclinic Luxembourg S a r l*

ИEDICLINIC GROUP LIMITED

ɪOTES TO THE FINANCIAL STATEMENTS

OR THE YEAR ENDED 31 MARCH 2026

1 Loans to group companies

	2026 $'m	2025 $'m
Loan to Hirslanden AG	63	-
	63	-

The unsubordinated loan to Hirslanden AG is bears interest at SARON plus 2 62% and is repayable on demand

2 Trade and other receivables

	2026 $'m	2025 $'m
Prepayments	-	1
	-	1

3 Cash and cash equivalents

Cash and cash equivalents consist of balances with banks and cash on hand and are classified as financial assets measured at amortised cost Cash at banks comprises cash that can readily be converted into cash, whereas short term deposits are convertable in cash with a notice period up to 60 days

	2026 $'m	2025 $'m
Bank accounts	141	5
Short term deposits	-	123
	141	128

4 Creditors amounts falling due within one year

Short-term creditors are measured at the transaction price Other financial liabilities are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method

	2026 $'m	2025 $'m
Other creditors	1	-
	1	-

5 Called up share capital

Ordinary shares are classified as equity Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax from the proceeds

Ordinary shares of 10p each, translated to USD

Authorised, allotted and fully paid	No	$'m
At 1 April 2024	737 243 810	108
Movements during the year	-	-
At 31 March 2025	737 243 810	108
Movements during the year	-	-
At 31 March 2026	737 243 810	108

Capital risk management

The company's objective when managing capital (which includes share capital working capital and cash and cash equivalents) is to maintain a flexible capital structure that reduces the cost of capital to an acceptable level of risk and to safeguard the company's ability to continue as a going concern while taking advantage of strategic opportunities in order to maximise stakeholder returns sustainably

MEDICLINIC GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

16 Subsidiary, associate and joint venture undertakings

Details of the Company's investments in subsidiary, associate and joint venture undertakings, including direct and indirect subsidiaries, associates and joint ventures, are set out below

SUBSIDIARIES

Company	Registered office address	Country of incorporation and place of business	Principal activities	Interest in capital 31 March 2026 %	Interest in capital 31 March 2025 %
Mediclinic CHF Finco Limited	IFC 5, St Helier, Jersey, JE1 1ST	Jersey	Treasury	**100 0**	100 0
Mediclinic Holdings Netherlands B V (deregistered effective 25 March 2026)	Schiekade 830, 3032 AL Rotterdam	Netherlands	Intermediary holding company	-	100 0
Mediclinic International (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Intermediary holding company	**100 0**	100 0
Mediclinic Middle East Holdings Limited	IFC 5, St Helier, Jersey, JE1 1ST	Jersey	Intermediary holding company	**100 0**	100 0
Mediclinic IPCo Holdings Limited*	19th Floor, 51 Lime Street, London, EC3M 7DQ	United Kingdom	Intermediary holding company	**100 0**	100 0
Mediclinic KSA Holdco B V	Schiekade 830, 3032 AL Rotterdam	Netherlands	Intermediary holding company	**100 0**	100 0
Mediclinic Luxembourg S à r l	14 Rue Edward Steichen, L-2540 Luxembourg	Luxembourg	Intermediary holding company	**100 0**	100 0
INDIRECTLY HELD THROUGH MEDICLINIC IPCO HOLDINGS LIMITED					
Ouroboros Solutions AG	Sihlbruggstrasse 3, 6340 Baar	Switzerland	Intermediary holding company	**100 0**	100 0
Phoenix Health And Wellness Solutions S L (deregistered effective 16 July 2025)	Calle de Muntaner, 292, 4º - 2ª, 08021, Barcelona	Spain	Intermediary holding company	-	100 0
INDIRECTLY HELD THROUGH MEDICLINIC CHF FINCO LIMITED					
Mediclinic Jersey Limited	IFC 5, St Helier, Jersey, JE1 1ST	Jersey	Intermediary holding company	**100 0**	100 0
INDIRECTLY HELD THROUGH MEDICLINIC LUXEMBOURG S À R L					
Hirslanden AG	Boulevard Lilienthal 2, 8152 Glattpark (Opfikon)	Switzerland	Intermediary holding company and operating company of Hirslanden	**100 0**	100 0
INDIRECTLY HELD THROUGH HIRSLANDEN AG					
AndreasKlinik AG Cham	Rigistrasse 1, 6330 Cham	Switzerland	Healthcare services	**100 0**	100 0
Hirslanden Bern AG	Schanzlihalde 11, 3013 Bern	Switzerland	Healthcare services	**100 0**	100 0
Hirslanden Klinik Aarau AG	Schanisweg, 5000 Aarau	Switzerland	Healthcare services	**100 0**	100 0

MEDICLINIC GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

Mediclinic Group Limited has provided a guarantee under section 479C of the Companies Act 2006 over the liabilities of Mediclinic IPCo Holdings Limited (registered number 14085931) and Mediclinic Group Limited (registered number 08338604), which is therefore exempt from audit under the requirements of s479A-479C of the Companies Act 2006

MEDICLINIC GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

16 Subsidiary, associate and joint venture undertakings (continued)

Company	Registered office address	Country of incorporation and place of business	Principal activities	Interest in capital 31 March 2026 %	Interest in capital 31 March 2025 %
INDIRECTLY HELD THROUGH HIRSLANDEN AG (continued)					
Hirslanden Klinik Linde AG	Blumenrain 105, 2503 Biel/Bienne	Switzerland	Healthcare services	**100 0**	100 0
Hirslanden Klinik Am Rosenberg AG	Hasenbuhlstrasse 11, 9410 Heiden	Switzerland	Healthcare services	**100 0**	100 0
Hirslanden La Colline Grangettes SA	Chemin des Grangettes 7, c/o Clinique des Grangettes SA 1224 Chêne-Bougeries	Switzerland	Healthcare services	**90 0**	90 0
Hirslanden Lausanne SA	Avenue d'Ouchy 31, 1006 Lausanne	Switzerland	Healthcare services	**100 0**	100 0
Hirslanden OPERA AG	Boulevard Lilienthal 2, 8152 Glattpark (Opfikon)	Switzerland	Healthcare services	-	100 0
Hirslanden Precise AG	Forchstrasse 452, 8702 Zollikon	Switzerland	Healthcare services	**100 0**	100 0
Hirslanden Venture Capital AG	Boulevard Lilienthal 2, 8152 Glattpark (Opfikon)	Switzerland	Healthcare services	**100 0**	100 0
IMRAD SA	Avenue d'Ouchy 31, Clinique Bois-Cerf c/o Hirslanden Lausanne SA, 1006 Lausanne	Switzerland	Healthcare services	**75 0**	75 0
Klinik Birshof AG	Reinacherstrasse 28, 4142 Munchenstein	Switzerland	Healthcare services	**100 0**	99 9
Klinik St Anna AG	St Anna-Strasse 32, 6006 Luzern	Switzerland	Healthcare services	**100 0**	100 0
Klinik Stephanshorn AG	Brauerstrasse 95, 9016 St Gallen	Switzerland	Healthcare services	**100 0**	100 0
Radiotherapie Hirslanden AG	Rain 34, 5000 Aarau	Switzerland	Healthcare services	**100 0**	100 0
Hirslanden OPERA Zumikon AG	Morgental 35, 8126 Zumikon	Switzerland	Healthcare services	**100 0**	100 0
Hirslanden OPERA St Gallen AG	Schuppisstrasse 10, 9016 St Gallen	Switzerland	Healthcare services	**100 0**	100 0
Hirslanden OPERA Bern AG	Nordring 4, 3013 Bern	Switzerland	Healthcare services	**100 0**	100 0
ZLZ Zentrallabor AG	Forchstrasse 454, 8702 Zollikon	Switzerland	Healthcare services	**85 0**	-
INDIRECTLY HELD THROUGH HIRSLANDEN KLINIK AM ROSENBERG AG					
Klinik am Rosenberg Heiden AG	Hasenbuhlstrasse 11, 9410 Heiden	Switzerland	Healthcare services	-	99 2
INDIRECTLY HELD THROUGH HIRSLANDEN BERN AG					
Medical Center Wankdorf AG	Papiermuhlestrasse 79, 3014 Bern	Switzerland	Healthcare services	**90 0**	90 0
INDIRECTLY HELD THROUGH KLINIK STEPHANSHORN AG					
Radiologie Neudorf AG, St Gallen	Rorschacher Strasse 286, 9016 St Gallen	Switzerland	Healthcare services	-	100 0

IEDICLINIC GROUP LIMITED

IOTES TO THE FINANCIAL STATEMENTS

OR THE YEAR ENDED 31 MARCH 2026

16 Subsidıary , associate and joint venture undertakings (continued)

Company	Registered office address	Country of incorporation and place of business	Principal activities	Interest in capital 31 March 2026 %	Interest in capital 31 March 2025 %
INDIRECTLY HELD THROUGH HIRSLANDEN LA COLLINE GRANGETTES SA					
Hirslanden Clinique La Colline SA	Avenue de Beau-Séjour 6, 1206 Genève	Switzerland	Healthcare services	**90 0**	90 0
Grangettes Healthcare SA	Chemin des Grangettes 7, c/o Clinique des Grangettes SA 1224 Chêne-Bougeries	Switzerland	Healthcare services	**90 0**	90 0
INDIRECTLY HELD THROUGH GRANGETTES HEALTHCARE SA					
Clinique des Grangettes SA	Chemin des Grangettes 7, c/o Clinique des Grangettes SA 1224 Chêne-Bougeries	Switzerland	Healthcare services	**90 0**	90 0
Dianecho SA	Rue de Carouge 116, 1205 Genève	Switzerland	Healthcare services	**65 8**	65 8
INDIRECTLY HELD THROUGH CLINIQUE DES GRANGETTES HEALTHCARE SA					
SI ROUTE DE CHENE A SA	Chemin des Grangettes 7, c/o Clinique des Grangettes SA 1224 Chêne-Bougeries	Switzerland	Healthcare services	**90 0**	90 0
INDIRECTLY HELD THROUGH HIRSLANDEN OPERA AG					
Hirslanden OPERA Zumikon AG	Morgental 35, 8126 Zumikon	Switzerland	Healthcare services	**100 0**	100 0
Hirslanden OPERA St Gallen AG	Schuppisstrasse 10, 9016 St Gallen	Switzerland	Healthcare services	**100 0**	100 0
Hirslanden OPERA Bern AG	Nordring 4, 3013 Bern	Switzerland	Healthcare services	**100 0**	100 0
INDIRECTLY HELD THROUGH IMRAD SA					
Hirslanden Freiburg AG, Dudingen	Bahnhofplatz 2a, 3186 Dudingen	Switzerland	Healthcare services	**75 0**	75 0
INDIRECTLY HELD THROUGH MEDICLINIC INTERNATIONAL (PTY) LIMITED					
Mediclinic Group Services (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Provision of group services within Mediclinic	**100 0**	100 0
Mediclinic Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Provision of group services within Mediclinic	**100 0**	100 0
INDIRECTLY HELD THROUGH MEDICLINIC GROUP SERVICES (PTY) LIMITED					
Medical Innovations (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street Stellenbosch 7600	South Africa	Hospital equipment and procurement	**100 0**	100 0
ER24 International (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Emergency medical services	**100 0**	100 0
INDIRECTLY HELD THROUGH ER24 INTERNATIONAL (PTY) LIMITED					
ER24 Lesotho (Pty) Limited	160 Constitution Road Maseru Central CCL Building	Lesotho	Healthcare services	**100 0**	100 0

10 Subsidiary, associate and joint venture undertakings (continued)

Company	Registered office address	Country of incorporation and place of business	Principal activities	Interest in capital 31 March 2026 %	Interest in capital 31 March 2025 %
INDIRECTLY HELD THROUGH MEDICLINIC INVESTMENTS (PTY) LIMITED					
Mediclinic Southern Africa (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Intermediary holding company	**100 0**	100 0
INDIRECTLY HELD THROUGH MEDICLINIC SOUTHERN AFRICA (PTY) LIMITED					
Curamed Holdings (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Intermediary holding company	**71 7**	73 0
Mediclinic Denmar Mental Health (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Mental healthcare services	**96 4**	96 4
Mediclinic Crescent Mental Health (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Mental healthcare services	**100 0**	100 0
ER24 Holdings (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Intermediary holding company	**100 0**	100 0
Intercare Group Hospital Holdings (Pty) Limited (Hospitals)	6th Floor Menlyn Central Towers, 125 Dallas Avenue, Menlyn, Pretoria 0181	South Africa	Healthcare services	**59 2**	59 2
Medical Human Resources (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Management of healthcare staff	**100 0**	100 0
Mediclinic (Pty) Limited (ordinary shares and Mediclinic Head Office Hospital shares)	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Intermediary holding company and operating company of Mediclinic Southern Africa	**100 0**	100 0
Mediclinic Brits (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**65 4**	64 3
Mediclinic Finance Corporation (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Treasury	**100 0**	100 0
Mediclinic Holdings (Namibia) (Pty) Limited	Grant Thornton Neuhaus, 12th floor, Sanlam Centre, 157 Independence Avenue, Windhoek	Namibia	Intermediary holding company	**100 0**	100 0
Mediclinic Lephalale (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**95 3**	95 3

ⱯEDICLINIC GROUP LIMITED

ⱯOTES TO THE FINANCIAL STATEMENTS

OR THE YEAR ENDED 31 MARCH 2026

16 Subsidiary , associate and joint venture undertakings (continued)

Company	Registered office address	Country of incorporation and place of business	Principal activities	Interest in capital 31 March 2026 %	Interest in capital 31 March 2025 %
INDIRECTLY HELD THROUGH MEDICLINIC SOUTHERN AFRICA (PTY) LIMITED (continued)					
Mediclinic Midstream (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**82 0**	82 0
Mediclinic Paarl (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**81 3**	81 3
Mediclinic Properties (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street Stellenbosch 7600	South Africa	Property ownership and management	**100 0**	100 0
Mediclinic Renal Services (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**78 6**	78 6
Mediclinic Renal Services Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**79 0**	79 0
Mediclinic Stellenbosch (Pty) Limited	Mediclinic Corporate Office 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**99 8**	96 7
Mediclinic Tzaneen (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**55 6**	55 6
Newcastle Private Hospital (Pty) Limited (50% plus one share, including B class shares)	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**58 8**	56 9
Practice Relief (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Provision of debt collection and related services	**100 0**	100 0
Victoria Hospital (Pty) Limited (50% plus five shares, including B class shares)	Mediclinic Corporate Office, 25 Du Toit Street Stellenbosch 7600	South Africa	Healthcare services	**52 0**	51 9
Sandton Day Hospital (Pty) Limited	6th Floor Menlyn Central Towers, 125 Dallas Avenue, Menlyn, Pretoria, 0181, South Africa	South Africa	Healthcare services	**70 0**	70 0
Sandton Sub-Acute Hospital (Pty) Limited	6th Floor Menlyn Central Towers, 125 Dallas Avenue, Menlyn, Pretoria, 0181, South Africa	South Africa	Healthcare services	**70 0**	70 0
Mediclinic Precise (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**100 0**	80 0
Mediclinic Imaging Holdings (Pty) Limited (Operations ceased in September 2025, to be deregistered)	Mediclinic Corporate Office, 25 Du Toit Street Stellenbosch 7600	South Africa	Healthcare services	**100 0**	100 0

MEDICLINIC GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

16 Subsidiary, associate and joint venture undertakings (continued)

Company	Registered office address	Country of incorporation and place of business	Principal activities	Interest in capital 31 March 2026 %	Interest in capital 31 March 2025 %
INDIRECTLY HELD THROUGH MEDICLINIC SOUTHERN AFRICA (PTY) LIMITED (continued)					
Mediclinic Imaging Equipment (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**100 0**	100 0
George Day Hospital (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**100 0**	100 0
Mediclinic Pathology (Pty) Ltd	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**50 0**	50 0
INDIRECTLY HELD THROUGH CURAMED HOLDINGS (PTY) LIMITED					
Curamed Hospitals (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**100 0**	100 0
Curamed Properties (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street Stellenbosch 7600	South Africa	Property ownership and management	**100 0**	100 0
INDIRECTLY HELD THROUGH CURAMED HOSPITALS (PTY) LIMITED					
Mediclinic Thabazimbi (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**76 0**	76 0
INDIRECTLY HELD THROUGH ER24 HOLDINGS (PTY) LIMITED					
ER24 EMS (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Emergency medical services	**100 0**	100 0
ER24 Trademarks (Pty) Limited (deregistered)	Mediclinic Corporate Office 25 Du Toit Street, Stellenbosch 7600	South Africa	Intellectual property holding company	**-**	100 0
ER24 Lesotho (Pty) Limited	160 Constitution Road Maseru Central CCL Building	Lesotho	Healthcare services	**-**	100 0
INDIRECTLY HELD THROUGH MEDICLINIC (PTY) LIMITED					
Mediclinic Ermelo (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**73 8**	68 7
Mediclinic Hermanus (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**53 2**	53 2
Mediclinic Kimberley (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**84 5**	85 3
Mediclinic Limpopo (Pty) Limited (50% plus one share)	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**50 0**	51 7
Mediclinic Potchefstroom (Pty) Limited	Mediclinic Corporate Office 25 Du Toit Street Stellenbosch 7600	South Africa	Healthcare services	**88 0**	88 2

MEDICLINIC GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

16 Subsidiary , associate and joint venture undertakings (continued)

Company	Registered office address	Country of incorporation and place of business	Principal activities	Interest in capital 31 March 2026 %	Interest in capital 31 March 2025 %
INDIRECTLY HELD THROUGH MEDICLINIC (PTY) LIMITED					
Mediclinic Upington (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**50 0**	50 0
INDIRECTLY HELD THROUGH MEDICLINIC LIMPOPO (PTY) LIMITED					
Mediclinic Limpopo Day Clinic (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**57 4**	59 2
Mediclinic Limpopo Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Investment holding company	**100 0**	100 0
HOSPITAL INVESTMENT COMPANIES					
Mediclinic Bloemfontein Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**98 1**	98 1
Mediclinic Cape Gate Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**93 8**	93 8
Mediclinic Cape Town Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**92 0**	93 2
Mediclinic Constantiaberg Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**78 7**	78 7
Mediclinic Durbanville Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**85 7**	88 0
Mediclinic Emfuleni Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**81 1**	81 1
Mediclinic George Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**99 2**	99 5
Mediclinic Highveld Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**91 2**	91 2
Mediclinic Hoogland Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**96 2**	97 4
Mediclinic Klein Karoo Investments (Pty) Limited	Mediclinic Corporate Office 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**100 0**	100 0
Mediclinic Legae Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**84 4**	84 8
Mediclinic Louis Leipoldt Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**99 9**	99 9

MEDICLINIC GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

16 Subsidiary, associate and joint venture undertakings (continued)

Company	Registered office address	Country of incorporation and place of business	Principal activities	Interest in capital 31 March 2026 %	Interest in capital 31 March 2025 %
HOSPITAL INVESTMENT COMPANIES (continued)					
Mediclinic Milnerton Investments (Pty) Limited	Mediclinic Corporate Office 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**97 1**	97 2
Mediclinic Morningside Investments (Pty) Limited	Mediclinic Corporate Office 25 Du Toit Street Stellenbosch 7600	South Africa	Hospital investment company	**71 8**	71 7
Mediclinic Nelspruit Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**97 8**	97 8
Mediclinic Panorama Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**99 8**	99 8
Mediclinic Pietermaritzburg Investments (Pty) Limited	Mediclinic Corporate Office 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**75 0**	75 5
Mediclinic Plettenberg Bay Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**93 5**	93 5
Mediclinic Sandton Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**84 4**	88 4
Mediclinic Secunda Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**100 0**	100 0
Mediclinic Vereeniging Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**99 0**	99 0
Mediclinic Vergelegen Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**95 7**	95 8
Mediclinic Welkom Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**93 2**	93 2
Mediclinic Worcester Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Hospital investment company	**97 3**	97 3
INDIRECTLY HELD THROUGH MEDICLINIC BLOEMFONTEIN INVESTMENTS (PTY) LIMITED					
Mediclinic Bloemfontein Day Clinic Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Day case clinic investment company	**86 5**	85 7
INDIRECTLY HELD THROUGH MEDICLINIC CAPE GATE INVESTMENTS (PTY) LIMITED					
Mediclinic Cape Gate Day Clinic Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Day case clinic investment company	**81 2**	81 2

MEDICLINIC GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

OR THE YEAR ENDED 31 MARCH 2026

16 Subsidiary, associate and joint venture undertakings (continued)

Company	Registered office address	Country of incorporation and place of business	Principal activities	Interest in capital 31 March 2026 %	Interest in capital 31 March 2025 %
INDIRECTLY HELD THROUGH MEDICLINIC DURBANVILLE INVESTMENTS (PTY) LIMITED					
Mediclinic Durbanville Day Clinic Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Day case clinic investment company	**82 9**	82 8
INDIRECTLY HELD THROUGH MEDICLINIC NELSPRUIT INVESTMENTS (PTY) LIMITED					
Mediclinic Nelspruit Day Clinic Investments (Pty) Limited	Mediclinic Corporate Office 25 Du Toit Street Stellenbosch 7600	South Africa	Day case clinic investment company	**86 6**	86 6
INDIRECTLY HELD THROUGH MEDICLINIC PIETERMARITZBURG INVESTMENTS (PTY) LIMITED					
Mediclinic Pietermaritzburg Day Clinic Investments (Pty) Ltd	Mediclinic Corporate Office 25 Du Toit Street, Stellenbosch 7600	South Africa	Day case clinic investment company	**100 0**	100 0
INDIRECTLY HELD THROUGH MEDICLINIC VERGELEGEN INVESTMENTS (PTY) LIMITED					
Mediclinic Vergelegen Day Clinic Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Day case clinic investment company	**88 7**	88 7
INDIRECTLY HELD THROUGH MEDICLINIC WELKOM INVESTMENTS (PTY) LIMITED					
Welkom Medical Centre (Free State) (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**86 6**	86 6
INDIRECTLY HELD THROUGH MEDICLINIC HOLDINGS (NAMIBIA) (PTY) LIMITED					
Mediclinic Capital (Namibia) (Pty) Limited	Grant Thornton Neuhaus, 12th floor, Sanlam Centre, 157 Independence Avenue, Windhoek	Namibia	Investment holding company	**100 0**	100 0
Mediclinic Otjiwarongo (Pty) Limited	Grant Thornton Neuhaus, 12th floor, Sanlam Centre, 157 Independence Avenue, Windhoek	Namibia	Healthcare services	**100 0**	100 0
Mediclinic Properties (Swakopmund) (Pty) Limited	Grant Thornton Neuhaus, 12th floor, Sanlam Centre, 157 Independence Avenue, Windhoek	Namibia	Property ownership and management	**100 0**	100 0
Mediclinic Properties (Windhoek) (Pty) Limited	Grant Thornton Neuhaus, 12th floor, Sanlam Centre, 157 Independence Avenue, Windhoek	Namibia	Property ownership and management	**100 0**	100 0
Mediclinic Swakopmund (Pty) Limited	Grant Thornton Neuhaus, 12th floor, Sanlam Centre, 157 Independence Avenue, Windhoek	Namibia	Healthcare services	**99 3**	98 9
Mediclinic Windhoek (Pty) Limited	Grant Thornton Neuhaus, 12th floor, Sanlam Centre, 157 Independence Avenue, Windhoek	Namibia	Healthcare services	**98 3**	98 5

MEDICLINIC GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

16 Subsidiary, associate and joint venture undertakings (continued)

Company	Registered office address	Country of incorporation and place of business	Principal activities	Interest in capital 31 March 2026 %	Interest in capital 31 March 2025 %
INDIRECTLY HELD THROUGH MEDICLINIC STELLENBOSCH (PTY) LIMITED					
Mediclinic Stellenbosch Day Clinic (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Day case clinic investment company	**75 0**	77 0
Mediclinic Winelands (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Healthcare services	**50 1**	50 1
INDIRECTLY HELD THROUGH MEDICLINIC TZANEEN (PTY) LIMITED					
Mediclinic Tzaneen Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Investment holding company	**100 0**	100 0
INDIRECTLY HELD THROUGH MEDICLINIC VICTORIA HOSPITAL (PTY) LIMITED					
Victoria Hospital Investments (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	South Africa	Investment holding company	**100 0**	100 0
INDIRECTLY HELD THROUGH MEDICLINIC IMAGING HOLDINGS (PTY) LIMITED					
Mediclinic Diagnostic Imaging Services (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street Stellenbosch 7600	South Africa	Healthcare services	**100 0**	100 0
INDIRECTLY HELD THROUGH MEDICLINIC MIDDLE EAST HOLDINGS LIMITED					
Emirates Healthcare Holdings Limited	IFC 5, St Helier, Jersey, JE1 1ST	Jersey	Intermediary holding company	**100 0**	100 0
Mediclinic International Co Limited	19th Floor, 51 Lime Street, London, EC3M 7DQ	United Kingdom	Dormant	**100 0**	100 0
Mediclinic KSA Holdings Limited	IFC 5, St Helier, Jersey, JE1 1ST	Jersey	Intermediary holding company	**100 0**	100 0
INDIRECTLY HELD THROUGH EMIRATES HEALTHCARE HOLDINGS LIMITED					
Emirates Healthcare FZ-LLC	Dubai Production City –Floor 6 Publishing Pavilion Dubai UAE	The UAE	Investment in Healthcare Enterprises & Development	**100 0**	100 0
INDIRECTLY HELD THROUGH EMIRATES HEALTHCARE FZ LLC					
Delah Cafe FZ LLC (deregistered)	Ground floor, Mediclinic City Hospital, Building no 35 and 37, Dubai Healthcare City, Al Razi Street, Dubai	The UAE	Food and catering	**-**	100 0
Mediclinic Middle East Management Services FZ LLC	Floor 5-6 Publishing Pavilion, Dubai Production City, Dubai	The UAE	Healthcare Management Services	**100 0**	100 0
Mediclinic Al Qusais Clinic LLC	Plot no 284/243, Shop 3–5, Legend Middle East Building, Al Qusais industerial 2 Deira	The UAE	Healthcare services	**95 0**	95 0
Mediclinic City Hospital FZ LLC	Building no 35 and 37, Dubai Healthcare City, Al Razi Street, Dubai	The UAE	Healthcare services	**100 0**	100 0

MEDICLINIC GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

16 Subsidiary , associate and joint venture undertakings (continued)

Company	Registered office address	Country of incorporation and place of business	Principal activities	Interest in capital 31 March 2026 %	Interest in capital 31 March 2025 %
INDIRECTLY HELD THROUGH EMIRATES HEALTHCARE FZ LLC					
Mediclinic Clinics Investment LLC	Third floor, Dubai Mall, Parcel ID 345897, Dubai	The UAE	Healthcare services	**95 0**	95 0
Mediclinic Hospitals LLC (Airport Road Hospital)	Sheikh Mohamed Bin Butti Building Sheikh Khalifa Bin Zayed Street, Abu Dhabi	The UAE	Healthcare services	**100 0**	100 0
Mediclinic Ibn Battuta Clinic LLC	Shop 142, China Cluster, Retail Corp, Ibn Battuta Mall, Dubai	The UAE	Healthcare services	**95 0**	95 0
Mediclinic Mirdif Clinic LLC	Uptown Mirdif Building, Parcel no 321-224 Mirdif, Dubai	The UAE	Healthcare services	**95 0**	95 0
Mediclinic Parkview Hospital LLC	Mediclinic Middle East management services, FZ LLC Land, Bur Dubai, Al Barsha South 3, Dubai Parcel ID 673-1901	The UAE	Healthcare services	**95 0**	95 0
Pharma Light Medical Store LLC	Plot no 49, Musaffah, M38, Abu Dhabi	The UAE	Medical store/procurement	**95 0**	95 0
Welcare Hospitals Limited	IFC 5, St Helier, Jersey, JE1 1ST	Jersey	Healthcare services	**100 0**	100 0
Bourn Hall International MENA Limited (deregistered)	DLA Piper Middle East LLP PO Box 121662 Dubai UAE	The UAE	General Commercial Business	**-**	100 0
INDIRECTLY HELD THROUGH BOURN HALL INTERNATIONAL MENA LIMITED					
Bourn Hall LLC	Parcel ID 321-226, Office owned to Dubai International Properties, Dubai Martime City, UAE	The UAE	Fertility Centre	**100 0**	100 0

MEDICLINIC GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

16 Subsidiary, associate and joint venture undertakings (continued)

Company	Registered office address	Country of incorporation and place of business	Principal activities	Interest in capital 31 March 2026 %	Interest in capital 31 March 2025 %
INDIRECTLY HELD THROUGH MEDICLINIC HOSPITALS LLC (AL NOOR HOSPITAL)					
Al Noor Hospital Clinics - Al Ain LLC O P C	Al Ain Town Center, Sheikh Mohammed Bin Butti Al Hamed Building, Al Ain	The UAE	Healthcare Services	**100 0**	100 0
Al Madar Medical Center Pharmacy LLC O P C	Al Jimi, Al Jimi Ali Jumaa Ali Darmaki Building, Al Ain	The UAE	Healthcare services	**100 0**	100 0
Mediclinic – Al Mamora LLC O P C	Jabr Mohamed Ghanem Sultan Al Suwaidi, Al Mouror Street, Abu Dhabi Island	The UAE	Healthcare services	**100 0**	100 0
Mediclinic Khalifa City LLC O P C	Mabkhoot Saleh Al Mansouri Building, plot no 14, Eastern South 42, Sector 1, Khalifa City, Abu Dhabi	The UAE	Healthcare services	**100 0**	100 0
Mediclinic Hospitals – Al Musafah Specialty Clinics LLC O P C	Musafah Sh 10 Parcel ID 401, Floor no M,1&2 Huashel Saeed, Khaseeb Al Yakooubi Building, Abu Dhabi	The UAE	Healthcare services	**100 0**	100 0
Mediclinic Pharmacy – Al Musaffah 2 LLC O P C	Madinat Mohamed Bin Zayed, Sh 10 Parcel ID 401 Huashel Saeed, Khaseeb Al Yakooubi Building, Abu Dhabi	The UAE	Healthcare services	**100 0**	100 0
Ayadi Home Health Care LLC O P C	Shaabiyat Makam, No 4 Al Makam, Ground Floor, Office no 2, Mohamed Thaloob Salem Hamad Al Derei Building, Al Ain, Abu Dhabi	The UAE	Healthcare services	**100 0**	100 0
INDIRECTLY HELD THROUGH WELCARE HOSPITALS LIMITED (JERSEY)					
Mediclinic Welcare Hospital LLC	Nasser Abdullah Hussein Lootah Building, Deira, Al Garhood Dubai	The UAE	Healthcare services	**49 0**	49 0
INDIRECTLY HELD THROUGH BOURN HALL LLC					
Bourn Hall Pharmacy LLC S P C	*City Center Al Salama street* Al Saqr Property Management building	The UAE	Healthcare services	**100 0**	-

16 Subsidiary, associate and joint venture undertakings (continued)

JOINT VENTURES

Company	Country of incorporation and place of business	Principal activities	Interest in capital 31 March 2026 %	Interest in capital 31 March 2025 %
Mediclinic Pharmacies (Pty) Ltd	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	Healthcare services	**100 0**	100 0
Victoria Hospital Pharmacy (Pty) Ltd	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	Healthcare services	**52 0**	51 9
Wits University Donald Gordon Medical Centre (Pty) Limited	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	Healthcare services	**49 9**	49 9
WDGMC Pharmacy (Pty) Ltd	Mediclinic Corporate Office, 25 Du Toit Street, Stellenbosch 7600	Healthcare services	**49 9**	49 9
GRGB Santé SA,, en liquidation Geneve	Chemin de Beau-Soleil 20, 1206 Genève, Switzerland	Healthcare services	**45 0**	45 0
Centre de Chirurgie Ambulatoire (CCA) - HUG Hirslanden SA Genève 31	Rue Gabrielle-Perret-Gentil 4, c/o Les hôpitaux universitaires de Genève, 1205 Genève, Switzerland	Healthcare services	**45 0**	45 0
Radiologie Villa Fleurie SA, Genève	Chemin THURY 7 b, 1206 Genève	Healthcare services	**45 0**	45 0
Ambulante Klinik Meilen AG	c/o MRI Zentrum Mannedorf AG Huniweg 12a, 8706 Meilen, Switzerland	Healthcare services	**50 0**	50 0

MEDICLINIC GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

16 Subsidiary, associate and joint venture undertakings (continued)

ASSOCIATES

		Interest in capital	
Company	**Country of incorporation and place of business**	**31 March 2026 %**	31 March 2025 %
Listed			
Spire Healthcare Group plc (held through Mediclinic Jersey Limited)	3 Dorset Rise, London, EC4Y 8EN	**29.8**	29 8
Unlisted			
Intercare Holdings Proprietary Limited	6th Floor Menlyn Central Towers, 125 Dallas Avenue, Menlyn, Pretoria, 0181, South Africa	**40 1**	34 0
Icon Joint Venture Proprietary Limited	1st Floor Madison Square Park, 4 Howick Close, Tygerfalls, 7530, South Africa	**25 0**	25 0
Nanolabs Health Services Proprietary Limited	1 Discovery Place, Sandton, Johannesburg, 2196	**32 0**	-
Zentrallabor Zurich (ZLZ), Zurich	Forchstrasse 452, 8702 Zollikon	**43 4**	44 1
Baukonsortium Cham	Rigistrasse 1, 6330 Cham	**24 0**	24 0
EFG Parkierung Rigistrasse, Cham	Rigistrasse 1, 6330 Cham	**25 0**	25 0
Qlick and Care SA	Rue Le-Corbusier 241208 Genève	**18 0**	18 0
La Colline, Centre de Physiothérapie du Sport S à r l , Genève	Chemin Thury 7A, 1206 Geneve	**20 7**	20 7
Berner Prothetikzentrum (BPZ), Bern	Schanzlistrasse 39, 3013 Bern	**33 3**	33 3
Réseau du sein Lausanne S à r l	Avenue Alexandre-Vinet 19, 1004 Lausanne	**33 3**	33 3
Hystrix Medical AG	Bahnhofstrasse 47,4900 Langenthal	**8 0**	8 7
Al Murjan Medical Center Company Limited	Al Rawdah District, Prince Saud Al Faisal Street, Jeddah, 21573, Saudi Arabia	**0 0**	0 0
Zentrum fur die Frau AG	Blumenrain 91, 2503 Biel/Bienne	**30 0**	30 0
Medical & Performance Center AG	Rorschacher Strasse 286, 9016 St Gallen, Switzerland	**25 0**	25 0
Bluespace Ventures AG	Am Stadtrand 118600 Dubendorf, Switzerland	**21 4**	-

MEDICLINIC GROUP LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2026

17 Controlling parties

The immediate parent undertaking is Mediclinic Holdings Limited Copies of the Mediclinic Holdings Limited consolidated financial statements can be obtained from the Company's registered office and from the Companies House website

The immediate parent undertaking, Mediclinic Holdings Limited, is jointly owned by Remgro Limited, through various subsidiaries (Remgro Healthcare [Pty] Ltd, Remgro Health Ltd and Remgro Jersey GBP Ltd), and Investment Holding Limited S à r l

18 Post balance sheet events

On 21 May 2026, the Board proposed a final dividend of $26 9m for the year ending 31 March 2026, which was approved by the Company's shareholders on the same date

The directors are not aware of any other matter or circumstance arising since the end of the financial year that would significantly affect the operations of the Company or the results of its operations

19 Commitments

The Company does not have any financial commitments, guarantees or contingencies not included in the Statement of Financial Position